[Stimulation of endogenous secretion of the growth hormone. Today in diagnosis, tomorrow in therapy?].
BACKGROUND
Treatment with growth hormone (GH) restores the natural growth rate in children with growth hormone deficiency (GHD). This is, however, achieved only after daily injections extending over many years and therefore daily short-term hypersomatotropinaemia. Stimulation of endogenous secretion of GH e.g. by oral administration of growth hormone-releasing peptide (GHRP) may help in future to eliminate these adverse aspects. This treatment could be beneficial in patients with a stimulable endogenous GH secretion.


RESULTS
In order to find potential candidates for spontaneous secretion of GH the authors examined, using a test with sermoreline (GHRH1-29NH2), 31 children (21 boys) aged 5.8-16.5 years suffering from idiopathic (GHD), previously treated by daily GH injections. GH rose after stimulation with sermoreline to more than 14 mIU/l in 18/31 children (responders). The ratio of "responders" was higher in the sub-group of children with isolated GHD, as compared with multiple pituitary deficiency (p = 0.05) and insignificantly higher in the sub-group of children born by breech delivery (p = 0.13).


CONCLUSIONS
More than half the children treated nowadays with GH could profit in future from the method of spontaneous GH secretions. The success of this procedure is more likely in children with isolated GHD and in breech delivered children.
Lebl
J
J
Imunoanalytická laboratorr Kliniky nukleární medicíny 2 LF UK a FN Praha - Motol.
Pechová
M
M
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D008297:Male; D017337:Sermorelin / Q000627:therapeutic use*
D017337:Sermorelin; D013006:Growth Hormone